MAIA Director CHAOUKI STEVEN M bought 40,849 shares at $1.22 (+36.8% holdings); unprofitable biotech with concurrent cluster buys.
Director Chaouki Steven M purchased 40,849 shares at $1.22, adding $50.0K and increasing his holdings by 36.8% to 151,873 shares. The timing context is mixed: his prior trade at MAIA on 2024-03-14 posted a +218.0% 90-day return (well-timed), but his most recent MAIA purchase on 2024-11-01 declined 25.9% over 90 days. His cross-ticker track record shows 50.0% win rate on prior buys with a 90-day average return of +96.0%, though sample size is small. This purchase occurs within a 14-day cluster of 2 other insider buys, which warrants attention. Against this stands the company's $-8.9M net loss over its last full fiscal year and current market cap of $50.4M, placing Maia in a biotech-stage profile where executive purchasing alone cannot substitute for fundamental progress.
MAIA director Chaouki purchases 22,133 shares at $2.51 ($55.6K); joins cluster of 3 others buying within 14 days
Director Chaouki Steven M purchased 22,133 shares at $2.51, increasing his holdings by 24.9% to 111,024 shares post-transaction, amid a coordinated cluster pattern where 3 other insiders also bought MAIA within the past 14 days. This marks his second open-market purchase at MAIA; his prior March 2024 buy at the same ticker delivered 88.5% return within 30 days and 218.0% within 90 days, demonstrating consistent execution in timing. The current stock price of $2.88 sits 43.5% below the 52-week high of $5.10, yet Chaouki's cross-ticker track record shows a 100% 90-day win rate across 1 prior purchase, with average 90-day returns of 218.0%. MAIA remains unprofitable with net income of $-8,879,276.00, but the synchronized buying by multiple insiders and the director's repeated purchases at this ticker form a notable pattern requiring investor attention to underlying catalysts.
